By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Paratek Pharmaceuticals, Inc. 

75 Kneeland Street

Boston  Massachusetts  02111  U.S.A.
Phone: 617-275-0040 Fax: 617-275-0039


SEARCH JOBS
Paratek Pharmaceuticals, Inc. is a private biopharmaceuticals company engaged in the discovery and commercialization of new therapeutics that treat serious and life-threatening diseases. Paratek has a particular focus on developing new therapeutics for the infectious disease market to combat the problem of antibiotic resistance. Paratek was founded in 1996 by Dr. Stuart B. Levy, the world-renowned expert in antibiotic resistance and Professor of Molecular Biology and Microbiology and of Medicine at Tufts University School of Medicine, and by Dr. Walter Gilbert, the successful biotechnology entrepreneur and well-known Nobel Prize-winning Professor at Harvard University. Paratek was created to harness the 30+ years of research and discovery in mechanisms of antibiotic resistance and tetracycline chemistry by Dr. Levy and his scientific team at Tufts University School of Medicine.

Paratek has established two product development programs to identify and develop multiple products for the treatment of infectious diseases:

  • The Tetracycline Resistance Project (Tet Project), based on expertise in medicinal chemistry
  • The Multiple Antibiotic Resistance Project (Mar Project), based on novel discoveries in pathogen genomics

Senior Management:
Thomas J. Bigger, President & Chief Executive Officer
Stuart B. Levy, M.D., Chief Scientific Officer
Beverly A. Armstrong, Vice President & Chief Financial Officer
George C. Hillman, Executive Vice President & Chief Operating Officer
S. Ken Tanaka, Vice President of Research & Development
Dennis Molnar, Executive Director of Corporate Development

Board of Directors
Walter Gilbert, Ph.D., Chairman
Stuart B. Levy, M.D., Vice Chairman & CSO
Thomas J. Bigger, President & CEO, Director
Kalevi Kurkijarvi, Ph.D., Director
Kenneth J. Novack, Director
Sir Mark Richmond, Ph.D., Director
Patricia Smith, M.D., Director
Pieter Strijkert, Ph.D., Director

Last Updated: 04-23-02


Key Statistics


Email: ir@paratekpharm.com
Ownership: Private

Web Site: Paratek Pharmaceuticals, Inc.
Employees: 76
Symbol: 
 





Collaborations

GlaxoSmithKline 

UCSF 

Tufts University 





Company News
10 Biotech Stocks Analysts are Upbeat About in May 5/23/2016 8:24:58 AM
Paratek Pharmaceuticals, Inc. To Present Clinical Findings At ECCMID 2016 3/30/2016 10:37:18 AM
Paratek Pharmaceuticals, Inc. Expands Leadership Team 12/3/2015 7:53:30 AM
Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial And Operating Results 11/12/2015 8:35:16 AM
Paratek Pharmaceuticals, Inc. Initiates Omadacycline Phase III Clinical Study In Community Acquired Bacterial Pneumonia (CABP) 11/9/2015 7:48:43 AM
Paratek Pharmaceuticals, Inc. To Report Third Quarter 2015 Financial Results On November 12, 2015 11/5/2015 10:17:21 AM
Paratek Pharmaceuticals, Inc. Receives FDA Fast Track Designation For Omadacycline 11/5/2015 10:02:25 AM
Paratek Pharmaceuticals, Inc. Expands Leadership Team With Two New Hires 10/1/2015 8:13:44 AM
Paratek Pharmaceuticals, Inc.'s Omadacycline, Demonstrates Broad Spectrum Activity In Pathogens Relevant In Skin Infections, Community-Acquired Pneumonia And Urinary Tract Infections 9/21/2015 7:58:27 AM
Paratek Pharmaceuticals, Inc.'s Omadacycline, Demonstrates Broad Spectrum Activity In Pathogens Relevant In Skin Infections, Community-Acquired Pneumonia And Urinary Tract Infections 9/17/2015 6:04:32 AM
1234567
//-->